Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
May
20
2019
Location Matters – Manufacturing Insights from FDA’s Annual Report on Drug Quality Sheppard, Mullin, Richter & Hampton LLP
Dec
16
2014
Sandoz and Celltrion Decline the Invitation to Dance: Biosimilars Challenge the Applicability of the BPCIA’s Exchange Provisions Before Bringing Suit Sheppard, Mullin, Richter & Hampton LLP
Aug
30
2022
Charging for Investigational Drugs Under an IND Questions and Answers, Draft Guidance for Industry, August 2022 Sheppard, Mullin, Richter & Hampton LLP
Feb
19
2015
Go For De Novo: FDA’s Revised Approach to Medical Device Accessories Sheppard, Mullin, Richter & Hampton LLP
Sep
30
2019
CBD Industry Beware: The False Labeling Class Action Has Arrived Sheppard, Mullin, Richter & Hampton LLP
Oct
3
2019
Third Circuit Holds that SLUSA Does Not Preclude Class Action Opt-Outs from Pursuing Individual Actions Sheppard, Mullin, Richter & Hampton LLP
Oct
30
2019
BREAKING NEWS: USDA Releases Interim Final Hemp Rule Sheppard, Mullin, Richter & Hampton LLP
Jun
14
2023
FDA Issues Proposed Rule for Standardized and Accessible Patient Medication Information Sheppard, Mullin, Richter & Hampton LLP
Mar
5
2020
How FDA is Reacting to the Coronavirus, and 2020 Regulatory Priorities Sheppard, Mullin, Richter & Hampton LLP
Mar
11
2020
FDA Commissioner Signals Enforcement Policy, Advancement of Research for CBD Products Sheppard, Mullin, Richter & Hampton LLP
Sep
7
2023
Context is Key: FDA Sends a Strong Message About Efficacy Claims Sheppard, Mullin, Richter & Hampton LLP
Sep
28
2023
A Second Chance to Win Your Government Healthcare Contract Sheppard, Mullin, Richter & Hampton LLP
Nov
8
2023
OIG General Compliance Program Guidance November 2023 Sheppard, Mullin, Richter & Hampton LLP
May
11
2020
The Expansion of Cardiovascular Procedures in the ASC Setting Sheppard, Mullin, Richter & Hampton LLP
Dec
21
2023
Pharmaceutical Companies Have Rights if the Federal Government Seized their Patents Sheppard, Mullin, Richter & Hampton LLP
Jul
13
2020
FDA Announces Plans to Resume Domestic On-site Inspections Sheppard, Mullin, Richter & Hampton LLP
Mar
25
2024
PFAS in Food Packaging: The Beginning of the End? Sheppard, Mullin, Richter & Hampton LLP
Jun
23
2013
Federal Trade Commission (FTC) v. Actavis: What Does It Mean for Reverse-Payment Settlements? Sheppard, Mullin, Richter & Hampton LLP
Jul
4
2013
European Union (EU) Carbon Trading System Wins Parliament's Support Sheppard, Mullin, Richter & Hampton LLP
Jun
26
2018
Ninth Circuit Confirms that Class Action Plaintiffs Must Plausibly Establish Future Intent To Re-Purchase To Maintain Claims for Injunctive Relief Sheppard, Mullin, Richter & Hampton LLP
Oct
25
2021
AB-45: California Finally Welcomes Hemp Products To The Marketplace Sheppard, Mullin, Richter & Hampton LLP
Jan
7
2022
FDA Releases Guidance for Digital Health Tech Used in Clinical Investigations Sheppard, Mullin, Richter & Hampton LLP
May
1
2019
Yes, UCANN! Sheppard, Mullin, Richter & Hampton LLP
Jul
12
2019
What’s in the Bottle? FDA Announces New Blockchain Pilot Program for Tracking Drug Distribution Sheppard, Mullin, Richter & Hampton LLP
Jul
26
2019
Is Prescription Drug Pricing The Cure For Partisanship? Sheppard, Mullin, Richter & Hampton LLP
Dec
2
2022
Proposal to Overhaul Privacy Law Governing Substance Use Disorder Treatment Records Sheppard, Mullin, Richter & Hampton LLP
Dec
20
2022
Comment Period for “Healthy” Regulations Extended; But Consumer Class Actions Targeting “Health Halos” May Continue Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2019
FDA Issues Warning Letters to 15 Companies, Consumer Update on CBD Safety Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins